4 Patients Randomized. $1,250 Per Randomized Patient.

For sites participating in GSK-sponsored studies, sponsor visibility into site performance is a constant operational reality. Enrollment metrics are tracked. Sites that fall short face questions from clinical operations teams and, in some cases, reduced allocation in future studies. For this Vaccine study site, the enrollment gap was not large. Four additional randomized patients were needed. But the window to close it was not open-ended.

The site's internal capacity to generate incremental enrollment was limited. Active coordinators were managing existing screen-fail rates and ongoing protocol obligations. Adding a patient recruitment initiative on top of current workload was not operationally feasible without external support that carried its own performance accountability.

The requirement was specific: a partner who would commit to randomized patients, not screened leads.

The campaign delivered 4 randomized patients against a $5,000 investment, a cost per randomized patient of $1,250.

Per-patient site fees in sponsor-initiated Phase II-III studies typically range from $3,000 to $15,000 per randomized patient. At an estimated $3,000 to $15,000 per-patient site fee, 4 randomized patients represents a potential $12,000 to $60,000 in patient revenue against a $5,000 campaign investment.

For a site operating under sponsor performance visibility, the enrollment outcome carried additional value: the protocol was completed as scoped, and the site's enrollment record with the sponsor was preserved. The contractual randomization structure meant the site did not carry financial exposure for campaign underperformance.